Aerovate TherapeuticsAVTE
About: Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Employees: 51
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
101% more call options, than puts
Call options by funds: $553K | Put options by funds: $275K
1% more funds holding
Funds holding: 80 [Q1] → 81 (+1) [Q2]
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
7.87% less ownership
Funds ownership: 102.19% [Q1] → 94.32% (-7.87%) [Q2]
95% less capital invested
Capital invested by funds: $842M [Q1] → $45.1M (-$797M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 0 (-6) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for AVTE.